By playing, you agree to uListen's Terms and Privacy Policy and YouTube's Terms of Service.
Peter Attia MD230 ‒ Cardiovascular disease in women: prevention, risk factors, lipids, and more
Summaries, chapters, transcripts, and FAQs on this page are made by uListen, not YouTube.
At a glance
WHAT IT’S REALLY ABOUT
Women's Heart Disease: Early Prevention, Lipids, Pregnancy, Statins, Menopause and Trial Gaps
- Michos reports that cardiovascular mortality declines have stalled and are rising in younger and middle-aged women, driven by obesity, diabetes, and cardiometabolic disease, while many women still fear cancer more than heart disease.
- Both speakers argue that lifetime exposure to LDL/apoB matters more than 10-year risk scores, so treating earlier, particularly in younger adults and in women with familial hypercholesterolemia, is warranted.
- The conversation walks through female-specific factors including menstrual cycle lipid shifts, PCOS, parity, oral contraceptives, pregnancy, and the lipid and androgen changes of menopause.
- Michos explains that women benefit from statins as much as men but are less likely to be offered them and more likely to stop them, and she outlines her approach with statins, PCSK9 inhibitors, inclisiran, bempedoic acid, and Lp(a) therapies.
- They discuss menopausal hormone therapy as a symptom-driven choice rather than a heart-prevention tool, and Michos calls for more women in cardiovascular trials and trial leadership.
IDEAS WORTH REMEMBERING
5 ideasHeart disease progress has stalled and is reversing in some groups of women.
Michos says mortality is rising in younger women and fastest in women aged 45 to 64, and that heart disease may overtake cancer as the leading cause of death in younger women if trends continue.
Time exposure to LDL/apoB should drive treatment decisions, not just 10-year risk.
Both speakers argue that 10-year scores are dominated by age and ignore a causal agent. Michos tells patients she wants to prevent heart attacks over the next 40 years, not only the next 10.
Women are not protected from heart disease if they have FH, diabetes, or smoke.
The usual roughly 10-year female delay in ASCVD does not appear in FH, where women have the same early onset as men. Michos says about 30% of women with untreated FH will have a heart attack before 60.
Statins work in women, but women are undertreated.
Michos cites meta-analyses showing similar benefit by sex, yet women are less likely to be offered statins and more likely to decline or stop them, partly because of muscle symptoms and a large nocebo effect.
Pregnancy temporarily raises lipids and statin guidance is shifting.
Cholesterol, triglycerides, and LDL rise in pregnancy and fall afterward, and Michos still generally stops statins around conception and pregnancy. She notes the FDA removed its strongest warning, and a trial is testing pravastatin for preeclampsia prevention.
WORDS WORTH SAVING
5 quotesIt's never too late to implement prevention, but prevention is better implemented when started earlier.
— Erin Michos
I'm not just concerned about preventing a heart attack in the next 10 years. I want to prevent them from having a heart attack over the next 40 years.
— Erin Michos
You know, the really how we live the first half of our lives really influences our freedom from morbidity and mortality the second half of our lives.
— Erin Michos
You don't have to be good at a hobby to enjoy it.
— Erin Michos
It's basically a peashooter in a bazooka fight when we have big, big guns to reduce the risk of cardiovascular disease.
— Peter Attia
High quality AI-generated summary created from speaker-labeled transcript.
